Sequencing technologies have rapidly advanced over the last two decades, and cancer research has reaped the rewards. Scientists now have deeper knowledge of the genomic causes and implications of cancer. They have also identified novel disease biomarkers enabling improved diagnostics, prognostics, and therapy selection. Nonetheless, cancer is still a complex multifactorial disease, requiring many techniques to characterize the full range of genomic variation that can cause or contribute to the disease's initiation and progression.
Download this white paper from Oxford Nanopore Technologies to explore how nanopore sequencing can overcome traditional challenges and deliver more comprehensive insights into cancer genomics.
